Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EBIT (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of EBIT data on record, last reported at -$25.6 million in Q4 2021.

  • For Q4 2021, EBIT fell 123.81% year-over-year to -$25.6 million; the TTM value through Dec 2021 reached -$75.6 million, up 8.09%, while the annual FY2025 figure was -$333.4 million, 20.81% down from the prior year.
  • EBIT reached -$25.6 million in Q4 2021 per COGT's latest filing, down from -$19.8 million in the prior quarter.
  • Across five years, EBIT topped out at $2.2 million in Q4 2019 and bottomed at -$57.2 million in Q3 2020.
  • Average EBIT over 4 years is -$14.1 million, with a median of -$11.0 million recorded in 2018.
  • Peak YoY movement for EBIT: soared 124.88% in 2019, then tumbled 611.43% in 2020.
  • A 4-year view of EBIT shows it stood at -$9.0 million in 2018, then skyrocketed by 124.88% to $2.2 million in 2019, then crashed by 611.43% to -$11.5 million in 2020, then plummeted by 123.81% to -$25.6 million in 2021.
  • Per Business Quant database, its latest 3 readings for EBIT were -$25.6 million in Q4 2021, -$19.8 million in Q3 2021, and -$17.3 million in Q2 2021.